Harold Bernstein Sells 14,609 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 14,609 shares of Maze Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10. Following the sale, the chief marketing officer directly owned 14,609 shares in the company, valued at approximately $436,809.10. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, May 14th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.22, for a total transaction of $393,300.00.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $31.26 on Friday. The firm has a 50-day simple moving average of $26.02 and a 200-day simple moving average of $35.64. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -12.36 and a beta of 2.14. Maze Therapeutics, Inc. has a 52 week low of $10.98 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. On average, equities analysts predict that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MAZE. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. HC Wainwright lifted their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Truist Financial lowered their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Finally, Wedbush upped their target price on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and an average target price of $66.00.

Institutional Trading of Maze Therapeutics

Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics in the fourth quarter valued at approximately $39,000. Ameritas Investment Partners Inc. lifted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the fourth quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.